Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Burt

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Idrugs : the Investigational Drugs Journal|September 30, 2010
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1Jessica Burt
Chemical Communications (Cambridge, England)|February 7, 2004
The parallel synthesis of a disaccharide library using a solid phase, peptide-templated strategyJessica Burt, Tony Dean, Stuart Warriner
Addiction (Abingdon, England)|January 15, 2026
Varenicline for cannabis use disorder: A randomized controlled trialAimee L McRae-Clark, Kevin M Gray, Nathaniel L Baker, et al.
Open Forum Infectious Diseases|March 12, 2025
Antenatal Screening for Hepatitis B Virus in Uganda: Missed Opportunities for Diagnosis and TreatmentMelanie Etti, Hannah G Davies, Alexander Amone, et al.
Pulmonary Circulation|May 6, 2022
Critical role for the lung endothelial nonmuscle myosin light-chain kinase isoform in the severity of inflammatory murine lung injuryCarrie L Kempf, Saad Sammani, Tadeo Bermudez, et al.
Vaccine: X|March 18, 2024
Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic reviewHannah G Davies, Emma V Thorley, Rossul Al-Bahadili, et al.
Vaccine: X|August 14, 2025
Corrigendum to "Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic review". [Vaccine X, 2024 Feb 23;18:100464]Hannah G Davies, Emma V Thorley, Rossul Al-Bahadili, et al.
Scientific Reports|January 14, 2022
eNAMPT neutralization reduces preclinical ARDS severity via rectified NFkB and Akt/mTORC2 signalingTadeo Bermudez, Saad Sammani, Jin H Song, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Idrugs : the Investigational Drugs Journal|September 30, 2010
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1Jessica Burt
Chemical Communications (Cambridge, England)|February 7, 2004
The parallel synthesis of a disaccharide library using a solid phase, peptide-templated strategyJessica Burt, Tony Dean, Stuart Warriner
Addiction (Abingdon, England)|January 15, 2026
Varenicline for cannabis use disorder: A randomized controlled trialAimee L McRae-Clark, Kevin M Gray, Nathaniel L Baker, et al.
Open Forum Infectious Diseases|March 12, 2025
Antenatal Screening for Hepatitis B Virus in Uganda: Missed Opportunities for Diagnosis and TreatmentMelanie Etti, Hannah G Davies, Alexander Amone, et al.
Pulmonary Circulation|May 6, 2022
Critical role for the lung endothelial nonmuscle myosin light-chain kinase isoform in the severity of inflammatory murine lung injuryCarrie L Kempf, Saad Sammani, Tadeo Bermudez, et al.
Vaccine: X|March 18, 2024
Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic reviewHannah G Davies, Emma V Thorley, Rossul Al-Bahadili, et al.
Vaccine: X|August 14, 2025
Corrigendum to "Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic review". [Vaccine X, 2024 Feb 23;18:100464]Hannah G Davies, Emma V Thorley, Rossul Al-Bahadili, et al.
Scientific Reports|January 14, 2022
eNAMPT neutralization reduces preclinical ARDS severity via rectified NFkB and Akt/mTORC2 signalingTadeo Bermudez, Saad Sammani, Jin H Song, et al.
Pageof 1